

CellCarta offers a full range of validated genomic assays. With sites accredited by CAP and CLIA certifications, we provide the highest standard of quality. Our team has experience with several commercial assays and can provide custom development, including for cell and gene therapies. Contact us for any custom development.

Pre-Validated Custom Assays for CAR therapies

VCN - Target: WPRE - dPCR, quantitative assay	RCL - Target: VSVG - qPCR, qualitative assay	RCR - Target: RD114, GALV - qPCR, qualitative assay
--	---	--

Commercial Assays available

RT-qPCR	Sequencing	NanoString
Biofidelity Aspyre® – Lung assay	Pillar Biosciences OncoReveal - CDx pan-cancer solid tumor IVDR/FDA assay	nCounter® PanCancer Immune Profiling Panel*
Cobas PIK3CA Mutation Test	Pillar Biosciences OncoReveal - all RUO Panels	nCounter® PanCancer Pathways Panel*
Cobas BRAF V600 Mutation Test	Watchmaker RNA Library Prep Kits with Polaris® Depletion - without exome capture	nCounter® PanCancer Progression Panel*
Cobas KRAS Mutation Test	Watchmaker RNA Library Prep Kits with Polaris® Depletion - with exome capture	nCounter® PanCancer IO 360™ Panel*
Cobas EGFR Mutation Test Version 2	Illumina RNA prep with Enrichment (L) Tagmentation Kit	nCounter® TCR Diversity Panel*
Cobas BRAF/NRAS Mutation Test (LSR)	Illumina TSO500 HT Assay	Lymphoma Subtyping Test CodeSet
Cobas KRAS Mutation Test Version 2 (LSR)	Illumina TSO500 ctDNA V2 Assay	PAM50 CodeSet Gene Expression Profile for Breast Cancer
Promega OncoMate™ MSI Dx Analysis System	Illumina TSO Comp	
Qiagen Therascreen EGFR RGQ PCR Kit	10X Genomics Chromium - scRNA Seq	
Qiagen Therascreen PIK3CA RGQ PCR Kit	10X Genomics Visium - HD spatial transcriptomics	
Qiagen Therascreen KRAS RGQ PCR Kit	TWIST (WES, WGS)	
Qiagen Therascreen FGFR RGQ RT-PCR kit	Watchmaker Genomics DNA Library Prep with Fragmentation, followed by capture with the Twist Exome 2.0 probe set	
AmoyDx Pan Lung Cancer PCR Panel	Watchmaker (WES, WGS)	
	Whole Genome Sequencing - WGS: Watchmaker Genomics DNA Library Prep with Fragmentation	
	HLA typing (HLA-A, -B, -C, DRB1, -DQB1 & DPB1)	

* All commercially available nCounter panels can be run at CellCarta.

Commercial IVD Assays available by Mutations

EGFR mutations	KRAS mutations
therascreen EGFR RGQ PCR Kit - Detection of fourteen exon 19 deletions, two insertions in exon 20 and five point mutations (L858R, T790M, L861Q, G719A and S768I) - Using DNA extracted from FFPE cobas® EGFR Mutation Test - Detection of exon 19 deletions, exon 20 insertions, point mutations (G719X, T790M, S768I, L861Q and L858R) - Using DNA extracted from FFPE and ctDNA from plasma - Semi-quantitative info on ctDNA samples	therascreen KRAS RGQ PCR Kit - The kit is intended to discriminate between KRAS mutation-negative (wild-type) and cobas® EGFR Mutation Test KRAS mutant tumors. - Detection of 7 mutations in codons 12 and 13 (G12A, G12D, G12R, G12C, G12S, G12V, G13D) - Using DNA extracted from FFPE cobas® KRAS Mutation Test - Detection of mutations in codons 12, 13 and 61 - Using DNA extracted from FFPE

Commercial IVD Assays available by Mutations

BRAF mutations	FGFR mutations
therascreen BRAF V600E RGQ PCR Kit - Detection of V600E mutations - Using DNA extracted from FFPE CRC tumor tissues cobas® BRAF Mutation Test - Detection of V600E mutations - Using DNA extracted from FFPE	therascreen FGFR RGQ PCR Kit - Detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) - Using RNA extracted from FFPE
PIK3CA mutations	HLA Typing
therascreen PIK3CA RGQ PCR Kit - Detection of mutations in exon 15 and eleven mutations in exons 7, 9 and 20 (C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y) - Using DNA extracted from FFPE and ctDNA from plasma	NGSgo®-MX6-1 panel from GenDx - Test implemented for patient selection where the HLA type of the patient is instructive. - Multiplex PCR amplification of 6 HLA loci (HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1) followed by sequencing on Illumina MiSeq Nano flow cell

*All therascreen kits report for each sample which mutation is detected or not. They don't provide a quantitative assessment / the VAF (Variant Allele Frequency) of these mutations.

Partnering with the best players!
Ask us about our exclusivity with Biofidelity and recent strategic partnership with Pillar!



BR_GClist_2026-04-10

ABOUT CELLCARTA

Leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 9 facilities located in Canada, USA, Belgium, Australia and China.

www.cellcarta.com

HEADQUARTERS

201 President Kennedy Ave., Suite 3900
Montreal, Quebec, Canada H2X 3Y7
Phone: + 1 514 360 3600